Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA

K Kluzek; Gosia Srebniak; W Majer; A Ida; T Milecki; K Huminska; Robert van der Helm; A Silesian; TM Wrzesinski; J Wojciechowicz; Berna Beverloo; Z Kwias; HAR Bluyssen; J Wesoly

doi:10.18632/oncotarget.15331

Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA

K Kluzek, Gosia Srebniak, W Majer, A Ida, T Milecki, K Huminska, Robert van der Helm, A Silesian, TM Wrzesinski, J Wojciechowicz, Berna Beverloo, Z Kwias, HAR Bluyssen, J Wesoly

Clinical Genetics

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

26 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	28558-28574
Number of pages	17
Journal	Oncotarget
Volume	8
Issue number	17
DOIs	https://doi.org/10.18632/oncotarget.15331
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.18632/oncotarget.15331

REPUB_99569.pdfFinal published version, 7.69 MB

http://hdl.handle.net/1765/99569

Cite this

Kluzek, K., Srebniak, G., Majer, W., Ida, A., Milecki, T., Huminska, K., van der Helm, R., Silesian, A., Wrzesinski, TM., Wojciechowicz, J., Beverloo, B., Kwias, Z., Bluyssen, HAR., & Wesoly, J. (2017). Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. Oncotarget, 8(17), 28558-28574. https://doi.org/10.18632/oncotarget.15331

@article{246ab7e59b1e4e8693c86287f618ae60,

title = "Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA",

author = "K Kluzek and Gosia Srebniak and W Majer and A Ida and T Milecki and K Huminska and \{van der Helm\}, Robert and A Silesian and TM Wrzesinski and J Wojciechowicz and Berna Beverloo and Z Kwias and HAR Bluyssen and J Wesoly",

year = "2017",

doi = "10.18632/oncotarget.15331",

language = "Undefined/Unknown",

volume = "8",

pages = "28558--28574",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "17",

}

Kluzek, K, Srebniak, G, Majer, W, Ida, A, Milecki, T, Huminska, K, van der Helm, R, Silesian, A, Wrzesinski, TM, Wojciechowicz, J, Beverloo, B, Kwias, Z, Bluyssen, HAR & Wesoly, J 2017, 'Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA', Oncotarget, vol. 8, no. 17, pp. 28558-28574. https://doi.org/10.18632/oncotarget.15331

Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. / Kluzek, K; Srebniak, Gosia; Majer, W et al.
In: Oncotarget, Vol. 8, No. 17, 2017, p. 28558-28574.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA

AU - Kluzek, K

AU - Srebniak, Gosia

AU - Majer, W

AU - Ida, A

AU - Milecki, T

AU - Huminska, K

AU - van der Helm, Robert

AU - Silesian, A

AU - Wrzesinski, TM

AU - Wojciechowicz, J

AU - Beverloo, Berna

AU - Kwias, Z

AU - Bluyssen, HAR

AU - Wesoly, J

PY - 2017

Y1 - 2017

U2 - 10.18632/oncotarget.15331

DO - 10.18632/oncotarget.15331

M3 - Article

C2 - 28212566

SN - 1949-2553

VL - 8

SP - 28558

EP - 28574

JO - Oncotarget

JF - Oncotarget

IS - 17

ER -